Luminus maintains a very strong global intellectual property position in U.S., Japan, EU and other countries. The patent applications cover the Company’s LASSN™ nanotechnology platform and its drug development efforts. Luminus has additional patent applications pending that cover LASSN™ drugs that are in its development pipeline. Current coverage extends through 2039 and we are continually inventing and protecting new inventions which will expand and extend coverage beyond 2039.
